---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-23-000441"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:44:28.407807+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q2 revenue $6.9M (+6% YoY); cuts FY2023 revenue guidance to $31.0-32.5M

## Summary
- Q2 net revenue $6.9M (+6% YoY); Domestic Core +8%, International Core +17%.
- Net loss $2.5M ($0.05/sh) improved from $2.9M loss ($0.07/sh) prior year; gross margin 56.1%.
- Cuts FY2023 revenue guidance to $31.0-32.5M (11-17% growth) from prior $32.5-33.5M (17-20% growth).
- Appoints Tom Adams as CFO; submitted 510(k) for FREEDOM60 with Hizentra prefilled syringes.
- Reaffirms FY2023 gross margin 58-60% and year-end cash >$10.0M.

## SEC filing metadata
- accession: 0001161697-23-000441
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-23-000441
- JSON: https://secwatch.observer/filing/0001161697-23-000441.json
- Plain text: https://secwatch.observer/filing/0001161697-23-000441.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported the second quarter ended June 30, 2023 results: revenue $6,935,930, net income $ 2.5 million, EPS $(0.05) per diluted share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $6,935,930
  - Net income: $ 2.5 million
  - EPS: $(0.05) per diluted share
  - Result: reported results
  source text: 2023 Second Quarter Financial Results Three Months Ended June 30, Change from Prior Year 2023 2022 $ % Net Revenues Domestic Core $ 5,388,172 $ 4,996,791 $ 391,381 $ 7.8% International Core 1,117,004 951,485 165,519 17.4% Novel Therapies 430,754 598,352 (167,598 ) (28.0)% Total $ 6,935,930 $ 6,546,628 $ 389,302 $ 5.9% Total net revenue increased $0.4 million, or 6%, for the three months ending June 30, 2023, compared to last year. Domestic Core growth of 8% was primarily driven by increased growth in consumables and pumps, new accounts, and increased prefilled syringe adoption. International Core growth of 17% was driven by strength across several EU markets, and growing global immunoglobulin drug volume availability. Novel Therapies net revenue declined by 28% in primarily related to strong non-recurring engineering revenues in the comparable quarter last year as well as the timing of 2023 pipeline wins. Gross profit increased $0.5 million or 16% in the three months ended June 30, 202
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm
- Earnings Releases
  KORU Medical Systems, Inc. reported full year 2023 results: revenue $31.0 - $32.5 million. Guidance lowered.
  - Period: full year 2023
  - Revenue: $31.0 - $32.5 million
  - Guidance: lowered
  - Result: guidance update
  source text: Reducing full year 2023 net revenue guidance to $31.0 and $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 - $33.5 million, representing growth in the range of 17-20% ● Reaffirming 2023 gross margin between 58%-60% and a planned 2023 exit between 60%-62% ● Reaffirming cash balance at year-end 2023 greater than $10.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.